Today’s cyclodextrin:
HPβCD has recently been incorporated as a solubilizing agent in coformulations of ARVs in SIV-infected nonhuman primates. Although HPβCD has historically been considered inert, recent findings suggest that HPβCD may contribute to inflammation. The contribution of HPβCD was investigated to healthy macaque inflammation in vitro and in vivo and observed that HPβCD causes induction of sCD14 and IL-1β from myeloid cells in vitro and demonstrates that HPβCD stimulatory capacity varies by commercial source.
Please follow this link to the full article!
